Recurrent Stereotyped Episodes in Cerebral Amyloid Angiopathy: Response to Migraine Prophylaxis in Two Patients

por Paterson, R.W., Uchino, K., Emsley, H.C., Pullicino, P.
Publicado 2013

Cerebrospinal fluid markers including trefoil factor 3 are associated with neurodegeneration in amyloid-positive individuals

por Paterson, R W, Bartlett, J W, Blennow, K, Fox, N C, Shaw, L M, Trojanowski, J Q, Zetterberg, H, Schott, J M
Publicado 2014

Biomarkers in dementia: clinical utility and new directions

por Ahmed, R M, Paterson, R W, Warren, J D, Zetterberg, H, O'Brien, J T, Fox, N C, Halliday, G M, Schott, J M
Publicado 2014

A targeted proteomic multiplex CSF assay identifies increased malate dehydrogenase and other neurodegenerative biomarkers in individuals with Alzheimer's disease pathology

por Paterson, R W, Heywood, W E, Heslegrave, A J, Magdalinou, N K, Andreasson, U, Sirka, E, Bliss, E, Slattery, C F, Toombs, J, Svensson, J, Johansson, P, Fox, N C, Zetterberg, H, Mills, K, Schott, J M
Publicado 2016

Transitioning from cerebrospinal fluid to blood tests to facilitate diagnosis and disease monitoring in Alzheimer's disease

por Alawode, D. O. T., Heslegrave, A. J., Ashton, N. J., Karikari, T. K., Simrén, J., Montoliu‐Gaya, L., Pannee, J., O´Connor, A., Weston, P. S. J., Lantero‐Rodriguez, J., Keshavan, A., Snellman, A., Gobom, J., Paterson, R. W., Schott, J. M., Blennow, K., Fox, N. C., Zetterberg, H.
Publicado 2021